UPDATED: Sanofi's Lantus empire imperiled as EU recommends Lilly, Boehringer biosimilar
27.06.2014 / Fierce Pharma
Sanofi's Lantus is not only the best-selling diabetes drug in the world; it is one of the best selling drugs in the world with $7.6 billion in 2013 revenues. But the foundation for this juggernaut is starting to crack. The EU Friday recommended approval a biosimilar of Lantus developed by Eli Lilly and Boehringer Ingelheim.